Trials / Completed
CompletedNCT05939479
Antistaphylococcal Betalactam and Emergence of Resistance
Impact of Antistaphylococcal Penicillins and Cefazolin on the Emergence of Resistance in French Hospitals
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 644 (actual)
- Sponsor
- Central Hospital, Nancy, France · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Antistaphylococcal penicillins are recommanded as first-line agent in methicillin-suceptible Staphylococcus aureus bacteraemia. Several studies in progress are investigating the efficacy and safety of cefazolin compared with antistaphylococcal penicillins. Cefazolin has broader spectrum than antistaphylococcal penicillins. The hypothesis of this project is that cefazoline could be responsible for a higher rate of bacterial resistance. The aim is to study the association between the emergence of bacterial resistance and the consumption of cefazolin and antistaphylococcal penicillins.
Conditions
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2023-05-01
- Completion
- 2023-06-01
- First posted
- 2023-07-11
- Last updated
- 2025-08-08
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05939479. Inclusion in this directory is not an endorsement.